Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From operating room to radiotherapy planning: A technical innovation in sinonasal oncology.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

REFCOR guidelines for sinonasal adenocarcinoma.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

A review of clinical trial radiotherapy quality assurance: value, evolution and lessons.

Clinical and translational radiation oncology·2026
Same author

REFCOR good practice guidelines for radiotherapy in sinonasal carcinomas and mucosal melanomas.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

REFCOR guidelines for sinus and nasal cavity cancer.

European annals of otorhinolaryngology, head and neck diseases·2026
Same journal

Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

Critical reviews in oncology/hematology·2026
Same journal

Remodeling the Immune Microenvironment: Engineering IL-2 Variants to Overcome Clinical Bottlenecks in PD-1 Inhibitor plus Chemotherapy.

Critical reviews in oncology/hematology·2026
Same journal

Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted Management.

Critical reviews in oncology/hematology·2026
Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026
Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026
Same journal

Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

Critical reviews in oncology/hematology·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Chemoradiation in anaplastic thyroid carcinomas.

X S Sun1, S R Sun, N Guevara

  • 1Department of Radiation Oncology, Jean Minjoz University Teaching Hospital, Boulevard Flemming, Besançon F-25000, France.

Critical Reviews in Oncology/Hematology
|December 11, 2012
PubMed
Summary
This summary is machine-generated.

Anaplastic thyroid carcinoma (ATC) treatment requires prompt chemoradiation with surgery. Intensity-modulated radiation therapy (IMRT) shows promise for improving locoregional control in ATC management.

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Related Experiment Videos

Last Updated: May 16, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Area of Science:

  • Oncology
  • Radiotherapy
  • Surgical Oncology

Background:

  • Anaplastic thyroid carcinoma (ATC) is a rare and aggressive malignancy, accounting for 1-2% of all thyroid cancers.
  • Patients with ATC face a poor prognosis, with a median survival of only 3-10 months.
  • Existing treatment guidelines for ATC require updates, particularly concerning advanced irradiation techniques.

Purpose of the Study:

  • To update recommendations for radiation therapy (RT) in anaplastic thyroid carcinoma (ATC).
  • To evaluate the role of novel irradiation techniques in managing ATC.
  • To synthesize current evidence on the multimodal treatment of ATC.

Main Methods:

  • A comprehensive literature search was conducted in English and French.
  • Keywords included: anaplastic thyroid carcinoma, chemoradiation, radiation therapy, and surgery.
  • Evidence level remains limited due to the rarity of ATC and small retrospective studies.

Main Results:

  • Complete surgical debulking, when feasible without mutilation, is recommended for ATC.
  • Systematic chemoradiation following surgery is crucial due to the rapid tumor doubling time.
  • Intensity-modulated radiation therapy (IMRT) offers dosimetric advantages for improved locoregional control and organ sparing.

Conclusions:

  • Chemoradiation combined with debulking surgery is the primary treatment for anaplastic thyroid carcinoma (ATC).
  • External beam radiation therapy (EBRT) utilizing IMRT can enhance local control.
  • Concomitant taxane-doxorubicin chemoradiotherapy warrants further investigation for ATC treatment.